Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 17,116	$ 19,055
Prepaid expenses and other current assets	827	2,515
Total Current Assets	17,943	21,570
Property and equipment, net	872	905
Deposits and other assets	23	23
Total Assets	18,838	22,498
Current Liabilities:
Accounts payable	2,020	1,993
Accrued expenses	1,526	2,627
Warrant liabilities	4,083	14,821
Accrued employee benefits	2,074	313
Deferred rent	90	3
Total Current Liabilities	9,793	19,757
Long term deferred rent	402	492
Total Liabilities	10,195	20,249
Stockholders’ (Deficit) Equity:
Common stock, $0.001 par value; 350,000,000 shares authorized, 128,648,365 issued and 128,566,886 outstanding and 117,254,196 issued and 117,172,714 outstanding	129	117
Additional paid-in capital	192,545	175,762
Accumulated deficit	(194,170)	(172,034)
Total Synthetic Biologics, Inc. and Subsidiaries (Deficit) Equity	(1,496)	3,845
Non-controlling interest	(1,914)	(1,596)
Total Stockholders’ (Deficit) Equity	(3,410)	2,249
Total Liabilities and Stockholders’ (Deficit) Equity	18,838	22,498
Series A Preferred Stock [Member]
Current Liabilities:
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized; 120,000 and zero shares issued and outstanding	$ 12,053	$ 0